{
    "root": "783df888-cee2-442a-82ba-094261bf657f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "QUININE SULFATE",
    "value": "20250130",
    "ingredients": [
        {
            "name": "QUININE SULFATE",
            "code": "KF7Z0E0Q2B"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        }
    ],
    "indications": "Quinine sulfate capsule USP is a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria ( 1 ).",
    "contraindications": "Adults (â‰¥ 16 years of age): 648 mg (two capsules) every 8 hours for 7 days ( 2.1 ). Patients with severe chronic renal impairment: one loading dose of 648 mg (two capsules) followed 12 hours later by 324 mg (one capsule) every 12 hours for 7 days ( 2.2 ).",
    "warningsAndPrecautions": null,
    "adverseReactions": "Quinine sulfate is contraindicated in patients with the following: Prolongation of QT interval ( 4 ) Glucose-6-phosphate dehydrogenase (G6PD) deficiency ( 4 ) Myasthenia gravis ( 4 ) Known hypersensitivity to quinine, mefloquine, or quinidine ( 4 ) Optic neuritis ( 4 )"
}